24,998 Shares in CareDx, Inc (NASDAQ:CDNA) Bought by Hanseatic Management Services Inc.

Hanseatic Management Services Inc. purchased a new position in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 24,998 shares of the company's stock, valued at approximately $781,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC raised its holdings in shares of CareDx by 1,021.8% during the second quarter. GAMMA Investing LLC now owns 2,210 shares of the company's stock worth $34,000 after acquiring an additional 2,013 shares during the period. nVerses Capital LLC raised its holdings in shares of CareDx by 175.0% during the third quarter. nVerses Capital LLC now owns 3,300 shares of the company's stock worth $103,000 after acquiring an additional 2,100 shares during the period. Plato Investment Management Ltd acquired a new stake in shares of CareDx during the second quarter worth $62,000. Creative Planning acquired a new stake in shares of CareDx during the third quarter worth $204,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in shares of CareDx during the third quarter worth $206,000.

CareDx Stock Up 2.9 %

Shares of CDNA traded up $0.67 during mid-day trading on Thursday, hitting $23.88. 1,179,615 shares of the company's stock were exchanged, compared to its average volume of 904,142. CareDx, Inc has a 52 week low of $6.11 and a 52 week high of $34.84. The stock's 50-day simple moving average is $27.42 and its 200-day simple moving average is $20.99. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of -8.84 and a beta of 1.80.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.11. The firm had revenue of $82.88 million for the quarter, compared to analyst estimates of $80.04 million. CareDx had a negative return on equity of 54.34% and a negative net margin of 45.90%. The company's revenue was up 23.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.43) EPS. Analysts forecast that CareDx, Inc will post -0.83 earnings per share for the current fiscal year.

Insider Buying and Selling at CareDx

In other CareDx news, Director Peter Maag sold 35,552 shares of CareDx stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $33.04, for a total value of $1,174,638.08. Following the completion of the transaction, the director now directly owns 330,024 shares of the company's stock, valued at $10,903,992.96. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Alexander L. Johnson sold 21,557 shares of the business's stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $32.58, for a total transaction of $702,327.06. Following the completion of the transaction, the insider now owns 284,983 shares of the company's stock, valued at approximately $9,284,746.14. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Peter Maag sold 35,552 shares of the business's stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $33.04, for a total value of $1,174,638.08. Following the transaction, the director now directly owns 330,024 shares of the company's stock, valued at $10,903,992.96. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 91,340 shares of company stock valued at $3,025,415 in the last three months. Corporate insiders own 4.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CDNA. BTIG Research lowered their price target on shares of CareDx from $40.00 to $35.00 and set a "buy" rating on the stock in a research note on Tuesday. StockNews.com upgraded shares of CareDx from a "hold" rating to a "buy" rating in a research note on Thursday, October 17th. Wells Fargo & Company began coverage on shares of CareDx in a research note on Tuesday, August 27th. They issued an "underweight" rating and a $28.00 price target on the stock. Craig Hallum lifted their price target on shares of CareDx from $22.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, August 1st. Finally, The Goldman Sachs Group lifted their price target on shares of CareDx from $26.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $29.60.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.